Literature DB >> 15563507

Molecular dissection of the events leading to inactivation of the FMR1 gene.

Roberta Pietrobono1, Elisabetta Tabolacci, Francesca Zalfa, Ilaria Zito, Alessandra Terracciano, Umberto Moscato, Claudia Bagni, Ben Oostra, Pietro Chiurazzi, Giovanni Neri.   

Abstract

The analysis of a lymphoblastoid cell line (5106), derived from a rare individual of normal intelligence with an unmethylated full mutation of the FMR1 gene, allowed us to reconstruct the chain of molecular events leading to the FMR1 inactivation and to fragile X syndrome. We found that lack of DNA methylation of the entire promoter region, including the expanded CGG repeat, correlates with methylation of lysine 4 residue on the N-tail of histone H3 (H3-K4), as in normal controls. Normal levels of FMR1 mRNA were detected by real-time fluorescent RT-PCR (0.8-1.4 times compared with a control sample), but mRNA translation was less efficient (-40%), as judged by polysome profiling, resulting in reduced levels of FMRP protein (approximately 30% of a normal control). These results underline once more that CGG repeat amplification per se does not prevent FMR1 transcription and FMRP production in the absence of DNA methylation. Surprisingly, we found by chromatin immunoprecipitation that cell line 5106 has deacetylated histones H3 and H4 as well as methylated lysine 9 on histone H3 (H3-K9), like fragile X cell lines, in both the promoter and exon 1. This indicates that these two epigenetic marks (i.e. histone deacetylation and H3-K9 methylation) can be established in the absence of DNA methylation and do not interfere with active gene transcription, contrary to expectation. Our results also suggest that the molecular pathways regulating DNA and H3-K4 methylation are independent from those regulating histone acetylation and H3-K9 methylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15563507     DOI: 10.1093/hmg/ddi024

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

Review 1.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

2.  Defining the role of the CGGBP1 protein in FMR1 gene expression.

Authors:  Martina Goracci; Stella Lanni; Giorgia Mancano; Federica Palumbo; Pietro Chiurazzi; Giovanni Neri; Elisabetta Tabolacci
Journal:  Eur J Hum Genet       Date:  2015-08-26       Impact factor: 4.246

Review 3.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

Review 4.  Epigenetics, autism spectrum, and neurodevelopmental disorders.

Authors:  Sampathkumar Rangasamy; Santosh R D'Mello; Vinodh Narayanan
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

5.  The active FMR1 promoter is associated with a large domain of altered chromatin conformation with embedded local histone modifications.

Authors:  Nele Gheldof; Tomoko M Tabuchi; Job Dekker
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-04       Impact factor: 11.205

Review 6.  New perspectives on the biology of fragile X syndrome.

Authors:  Tao Wang; Steven M Bray; Stephen T Warren
Journal:  Curr Opin Genet Dev       Date:  2012-02-28       Impact factor: 5.578

7.  Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcription.

Authors:  Daman Kumari; Karen Usdin
Journal:  Hum Mol Genet       Date:  2014-07-23       Impact factor: 6.150

Review 8.  Fragile X syndrome.

Authors:  Wilmar Saldarriaga; Flora Tassone; Laura Yuriko González-Teshima; Jose Vicente Forero-Forero; Sebastián Ayala-Zapata; Randi Hagerman
Journal:  Colomb Med (Cali)       Date:  2014-12-30

Review 9.  Chromatin remodeling in the noncoding repeat expansion diseases.

Authors:  Daman Kumari; Karen Usdin
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

10.  Improved methodology for assessment of mRNA levels in blood of patients with FMR1 related disorders.

Authors:  David E Godler; Danuta Z Loesch; Richard Huggins; Lavinia Gordon; Howard R Slater; Freya Gehling; Trent Burgess; K H Andy Choo
Journal:  BMC Clin Pathol       Date:  2009-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.